Review of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder

Australasian Psychiatry

Volumn 12, Issue 4, 2004, Pages 369-375

  Hazell, Philip ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Adrenergic uptake inhibitors; Attention deficit disorder with hyperactivity; Delayed action preparations; Methylphenidate

Indexed keywords

AMPHETAMINE; ATOMOXETINE; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; METHYLPHENIDATE; MOCLOBEMIDE; NEW DRUG; PAROXETINE; SALBUTAMOL; TAMOXIFEN;

ABDOMINAL PAIN; APPETITE DISORDER; ATTENTION DEFICIT DISORDER; AUSTRALIA; BIOEQUIVALENCE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DISEASE CONTROL; DIZZINESS; DRUG BLOOD LEVEL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DEPENDENCE; DRUG DOSAGE FORM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUSTRY; DRUG INFORMATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENTERIC COATED TABLET; ERECTILE DYSFUNCTION; FATIGUE; HEADACHE; HEART ARRHYTHMIA; HUMAN; INSOMNIA; IRRITABILITY; LIBIDO DISORDER; MEDLINE; NAUSEA; NERVOUSNESS; OSMOTIC PUMP; PHARMACODYNAMICS; PHARMACY; PRESCRIPTION; QT PROLONGATION; REVIEW; SOMNOLENCE; SUSTAINED RELEASE PREPARATION; SWEAT GLAND DISEASE; VOMITING; WOLFF PARKINSON WHITE SYNDROME; XEROSTOMIA;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; AUSTRALIA; BIOLOGICAL AVAILABILITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG APPROVAL; DRUG COSTS; DRUG UTILIZATION; HUMANS; METABOLIC CLEARANCE RATE; METABOLIC DETOXICATION, DRUG; METHYLPHENIDATE; PERSONALITY ASSESSMENT; PROPYLAMINES; RANDOMIZED CONTROLLED TRIALS; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 12144273991     PISSN: 10398562     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1665.2004.02129.x     Document Type: Review

References (32)

1. Sawyer MG, Rey JM, Graetz BW, Clark JJ, Baghurst PA. Use of medication by young people with attention-deficit/hyperactivity disorder. Medical Journal of Australia 2002; 177: 21-25.
2. Hazell PL, McDowell MJ, Walton JM. Management of children prescribed psychostimulant medication for attention deficit hyperactivity disorder in the Hunter region of NSW. Medical Journal of Australia 1996; 165: 477-480.
3. Conners CK, Casat CD, Gualtieri CT et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. Journal of the American Academy of Child and Adolescent Psychiatry 1996; 35: 1314-1321.
4. Kuperman S, Perry PJ, Gaffney GR et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry 2001; 13: 129-134.
5. Wilens TE, Spencer TJ, Biederman J et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry 2001; 158: 282-288.
6. Niederhofer H. An open trial of buspirone in the treatment of attention-deficit disorder. Human Psychopharmacology 2003; 18 489-492.
7. Otka JE, Mercadante MT, Scahill L, Leckman JF. Reboxetine as a potentially effective treatment for attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology 2001; 11: 203-204.
8. Findling RL, Schwartz MA, Flannery DJ, Manos MJ. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. Journal of Clinical Psychiatry 1996; 57: 184-189.
9. Lyseng-Williamson KA, Keating GM. Extended-release methylphenidate (Ritalin LA). Drugs 2002; 62: 2251-2259.
10. Ramchandani P, Joughin C, Zwi M. Attention deficit hyperactivity disorder. In: Godlee F. Clinical Evidence. BMJ Publishing, 2003. http://www.clinicalevidence.org
11. Biederman J, Quinn D, Weiss M et al. Methylphenidate hydrochloride extended-release capsules (Ritalin LA): a new once-daily therapy for ADHD [Poster]. American Psychiatric Association 2002 Annual Meeting; May 18-23 Philadelphia (PA).
12. Lopez F, Silva R, Pestreich L, Muniz R. Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatric Drugs 2003; 5: 545-555.
13. Swanson J, Gupta S, Lam A et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Archives of General Psychiatry 2003; 60: 204-211.
14. Pelham WE, Gnagy EM, Burrows-Maclean L et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001; 107: E105.
15. Wolraich ML, Greenhill LL, Pelham W et al. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108 883-892.
16. Cox DJ, Merkel L, Penberthy JK, Kovatchev B, Hankin CL. Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study. Journal of the American Academy of Child and Adolescent Psychiatry 2004; 43: 269-275.
17. Spencer T, Biederman J, Wilens T et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. American Journal of Psychiatry 1998; 155 693-695.
18. Levy F, Farrow M. Working memory in ADHD: prefrontal/parietal connections. Current Drug Targets 2001; 2: 347-352.
19. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS. A double-blind placebo controlled study of desipramine in the treatment of ADD. I. Efficacy. Journal of the American Academy of Child and Adolescent Psychiatry 1989; 28: 777-784.
20. Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. Journal of the American Academy of Child and Adolescent Psychiatry 2003; 42: 886-894.
21. Michelson D, Allen AJ, Busner J et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. American Journal of Psychiatry 2002; 159: 1896-1901.
22. Michelson D, Faries D, Wernicke J et al, Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108 E83.
23. Caballero J, Nahata MC. Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder. Clinical Therapeutics 2003; 25: 3065-3083.
24. Michelson D, Adler L, Spencer T et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biological Psychiatry 2003; 53: 112-120.
25. Spencer T, Heiligenstein JH, Biederman J et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry 2002; 63: 1140-1147.
26. Allen AJ, Milton DR, Michelson D, Kelsey DK. Efficacy of atomoxetine treatment for adolescents with attention-deficit/hyperactivity disorder [Poster]. American Psychiatric Association 2003 Annual Meeting; May 17-22, San Francisco (CA).
27. Biederman J, Heiligenstein JH, Faries DE et al. Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics 2002; 110 E75.
28. Michelson D, Zhang S, Buitelaar J et al. Results from a long-term trial of atomoxetine in the prevention of relapse in ADHD [Poster]. American Psychiatric Association 2003 Annual Meeting; May 17-22, San Francisco (CA).
29. Kratochvil CJ, Heiligenstein JH, Dittmann R et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. Journal of the American Academy of Child and Adolescent Psychiatry 2002; 41: 776-784.
30. Alderton HR. Tricyclic medication in children and the OT interval: case report and discussion. Canadian Journal of Psychiatry 1995; 40: 325-329.
31. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. Journal of Clinical Psychiatry 2002; 63 (Suppl. 12): 50-55.
32. Heil SH, Holmes HW, Bickel WK et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug and Alcohol Dependence 2002; 67: 149-156.